Medically reviewed by Jurairat J. Molina, MD Acute urticaria (hives) is a common skin condition that affects up to 20% of people at some point in their lives. It can transition into chronic urticaria ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Novartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but the company says it has gone one better with new ...

While her research had quickly led her to believe that the itching and welts were hives, "I wasn't able to ... ethnic disparities in healthcare, and chronic conditions. Prior to joining PS ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

These OTC remedies are the best solution ... incidents of hives breakouts that tend to disappear within a few days, especially after you use antihistamines. If you have chronic hives, which ...

Opens in a new tab or window BOSTON -- Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous ... In addition, treatment with dupilumab ...

for the treatment of chronic spontaneous urticaria (CSU) in adults and pediatric patients aged 12 years and older inadequately controlled with H1 antihistamine treatment. The original sBLA was ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

The mainstay of treatment for urticaria is oral ... especially in aspirin-sensitive urticaria. Nifedipine has a small effect in chronic urticaria, and is often used for patients with concomitant ...

Novartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but the company says it has gone one better with new ...